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and prognosis in colorectal cancer
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Abstract 
Background: Tapasin is a crucial component of the major histocompatibility (MHC) class I antigen presentation 
pathway. Defects in this pathway can lead to tumor immune evasion. The aim of this study was to test whether tapa-
sin expression correlates with CD8+ cytotoxic T lymphocyte (CTL) infiltration of colorectal cancer (CRC) and overall 
survival.
Methods: A next-generation tissue microarray (ngTMA) of 198 CRC patients with full clinicopathological informa-
tion was included in this study. TMA slides were immunostained for tapasin, MHC I and CD8. Marker expression was 
analyzed with immune-cell infiltration, patient survival and TNM-staging.
Results: A reduction of tapasin expression strongly correlated with venous invasion (AUC 0.682, OR 2.7, p = 0.002; 
95 % CI 1.7–5.0), lymphatic invasion (AUC 0.620, OR 2.0, p = 0.005; 95 % CI 1.3–3.3), distant metastasis (AUC 0.727, OR 
2.9, p = 0.004; 95 % CI 1.4–5.9) and an infiltrative tumor border configuration (AUC 0.621, OR 2.2, p = 0.017; 95 % CI 
1.2–4.4). Further, tapasin expression was associated with CD8+ CTL infiltration (AUC 0.729, OR 5.4, p < 0.001; 95 % CI 
2.6–11), and favorable overall survival (p = 0.004, HR 0.6, 95 % CI 0.42–0.85).
Conclusions: Consistent with published functional data showing that tapasin promotes antigen presentation, as 
well as tumor immune recognition and destruction by CD8+ CTLs, a reduction in tapasin expression is associated with 
tumor progression in CRC.
Keywords: Colorectal cancer, Prognostic factor, Immune infiltration, Tapasin, MHC I, Antigen presentation, CD8, 
Cytotoxic lymphocytes, Immune activation, Immunosurveillance
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Background
The ability of the immune system to recognize and 
attack tumor cells is being acknowledged as an increas-
ingly important factor in overall disease progression 
[1–3]. Specifically, in colorectal cancer (CRC), increased 
tumor infiltration by CD4+ and CD8+ T-lymphocytes 
(CTLs) correlates positively with overall (OS) and dis-
ease-free survival (DFS) [2].The surface presentation 
of antigenic peptides by the Major Histocompatibility 
Complex class I molecules (MHC I) is indispensable for 
the initiation of the CD8+ T-lymphocyte anti-tumoral 
immune response. The MHC I consists of the heavy 
α-chain (HLA) and a β2-microglobulin (B2M) chain. 
Folding and assembly is assisted by the chaperone cal-
nexin. The antigenic peptides are generated by the 
proteasome and loaded into the assembled MHC I mol-
ecule through a multi-step process involving (1) trans-
location of the peptides into the endoplasmic reticulum 
by TAP1/2 proteins, and (2) binding of the peptides 
to assembled MHC I molecules facilitated by the pep-
tide loading complex (TAP1, TAP2, calreticulin, ERp57 
and tapasin). A conformational change in the molecule 
resulting from peptide binding releases the MHC I from 
the loading complex and allows surface presentation of 
the antigen [4, 5].
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Tapasin is an essential member of the MHC I pathway. 
On a molecular level, it is a transmembrane glycoprotein 
which forms a stable heterodimer with the thiol oxidore-
ductase ERp57 [6]. Cells missing tapasin have reduced 
MHC I surface expression [7], and display MHC I mol-
ecules loaded with suboptimal, low affinity peptides [8], 
resulting in decreased CTL recognition [9]. Loss of tapa-
sin therefore contributes to reduced immunogenicity and 
immune evasion of tumors [10]. The importance of tapa-
sin for antigen presentation in cancer was first shown 
in vivo in mouse tumor models. Mice were injected with 
a lung carcinoma cell line in which many components of 
the MHC I pathway were downregulated. Transfection of 
tapasin on this background was sufficient to restore anti-
gen presentation, increase  the antigen-specific immune 
response, reduce tumor growth, and increase survival 
[11]. However, the potential effect of tapasin on patient 
outcome in human CRC has not been determined to 
date. The aim of this study was therefore to test whether 
tapasin expression correlates with the degree of CTL 
infiltration and overall survival in CRC and thus influ-
ences overall survival.
Methods
Patients
This study was designed to comply with the reporting 
recommendations for tumor marker prognostic studies 
(REMARK) guidelines for tumor marker prognostic stud-
ies. The study design is shown in Additional file 1: Figure 
S1. 220 non-consecutive surgically treated CRC patients 
treated from 2004 to 2007 at the Areteiaion University 
Hospital, University of Athens, Greece, were retrospec-
tively included in this study. Clinical data were obtained 
from patient records including patient age at diagnosis, 
gender, tumor location and diameter, and overall sur-
vival time. An experienced GI pathologist (EK) reviewed 
all histomorphological data of the surgical resections, 
and recorded data on pTNM classification, tumor grade, 
lymphatic and venous invasion, histological subtype and 
tumor border configuration. Clinicopathological fea-
tures of the 198 patients for which tapasin expression 
could be analyzed are listed in Additional file 2: Table S1. 
The median survival time was 58 months (95 % CI 50.9–
65.1  month). Detailed clinicopathological data for this 
cohort has been published [12]. The use of patient data 
has been approved by the local Ethics Committee of the 
University of Athens, Greece.
Assay methods
Using a digital pathology and automated tissue micro-
arraying approach, a next-generation tissue microar-
ray (ngTMA [13]) was constructed that included tissue 
spots from the tumor center (n = 2), tumor front (n = 2) 
and matched normal colorectal mucosa (n  =  1) from 
220 patients [13]. The ngTMA blocks were sectioned at 
4 µm and stained for MHC I with an established antibody 
[14] that detects the main human HLA types A, B and 
C (Abcam #ab70328, dilution 1:4000, pre-treatment cit-
rate 30′, 100 °C), for tapasin (Novus #NBP1-86968, dilu-
tion 1:50, pre-treatment tris 30′, 95 °C) and CD8 (Dako, 
#M7103, dilution 1:100, pre-treatment tris 20′, 90 °C) by 
automated immunohistochemistry using a standard pro-
tocol on a LEICA Bond-III.
Evaluation of immunohistochemistry
To detect the MHC I complex, we evaluated the percent-
age of cells which showed membranous expression of the 
classical heavy α-chain isoforms (HLA-ABC) in relation 
to the total number of cells in the spot under high power 
(400×) magnification. The expression varied between 
0 and 100 percent, with the median and mean scores 
being 30 and 23.8, respectively. Intratumoral lympho-
cytes and normal mucosa served as an internal positive 
control. CD8+ CTLs were counted in each spot. Because 
tapasin is ubiquitously expressed, immunoreactivity was 
assessed by scoring the staining intensity. The intensity 
was scored as 0–3, with 0 representing complete absence 
of marker reactivity, 1 as low staining intensity visible at 
200×, 2 as medium staining intensity visible at 100×, 3 as 
high staining intensity visible at all magnifications, based 
on an adaptation of the well-established protocol for the 
assessment of HER2 biomarker expression by Rüschoff 
and colleagues [15]. The expression varied between 0 and 
3 with the median and mean scores being 2.31 and 2.33, 
respectively. Normal mucosa served as an internal posi-
tive control.
Statistics
The association of protein markers with clinicopathologi-
cal features was analyzed by receiver operating charac-
teristic (ROC) curve analysis and logistic regression. The 
p values, odds ratios (OR) and 95 % CI for each analysis 
were obtained, as well as the area under the curve (AUC), 
with values closer to 1 indicating a better discriminatory 
ability for binary end point. For survival assessment using 
non-dichotomized data, Cox regression analyses were 
performed. After verification of the proportional haz-
ards assumption, multivariable Cox regression analysis 
was carried out using pT (primary tumor), pN (regional 
lymph nodes), pM (distant metastasis), adjuvant therapy 
(postoperative therapy, such as chemotherapy, radiother-
apy or combination therapies), CD8+ CTL infiltration 
and protein expression as possible confounding factors. 
Hazard ratios (HR) and 95 % CI were used to determine 
the effect size. Differences in survival time were displayed 
using standard Kaplan–Meier curves and tested using the 
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log-rank test in univariate analysis. The time of survival 
was defined as the time of an event occurrence (death) 
or censored (patient lost to follow-up) relative to the 
date of operation. Analyses were performed using SPSS 
Version 21.
Results
Analysis of tapasin and MHC I expression patterns 
in normal mucosa and CRC by immunohistochemistry
Tapasin expression in normal tissue was low to moder-
ate; the protein showed a cytoplasmic/membranous 
expression. The staining was diffuse and homogeneous 
in the majority of normal and tumor spots. MHC I was 
downregulated (score lower than the overall mean) in 
50.7  % of cases in normal mucosa and in 60  % cases of 
CRC tumors. Tapasin could be detected in the normal 
mucosa of 93 % of cases, and was downregulated in 48 % 
of tumors (p = 0.002). Representative IHC stainings can 
be seen in Fig. 1. Interestingly, only 2/19 available meta-
static cases showed tapasin expression (p = 0.002).
Association of tapasin expression with clinicopathological 
features and survival in CRC
Reduced tapasin expression was associated with venous 
invasion (AUC 0.682, p = 0.002, OR 2.70; 95 % CI 1.72–
5.0), lymphatic invasion (AUC 0.620, p = 0.005, OR 2.04; 
95 % CI 1.25–3.33), and the presence of distant metasta-
sis (AUC 0.727, p = 0.004, OR 2.86; 95 % CI 1.41–5.88). 
Low tapasin was also concurrent with an infiltrative 
tumor border configuration (AUC 0.621 p =  0.017, OR 
2.22; 95 % CI 1.15–4.35). The associations of tapasin with 
these and other clinicopathological features are listed in 
Table 1.
Univariate and multivariate survival analysis
High tapasin expression in the tumor was found to be a 
significant favorable prognostic factor (p = 0.004, HR 0.6, 
95  %  CI 0.42–0.85, Table  2). To visualize this effect, we 
dichotomized the tapasin values using the mean expres-
sion score to differentiate between 95 tapasin negative 
and 103 tapasin positive cases and plotted a Kaplan–
Meier curve (Fig.  2). The favorable prognostic effect of 
tapasin was independently maintained in multivariate 
analysis when adjusting for potential confounder factors 
such as patient age and gender, tumor grade, pT, tumor 
size and location, and adjuvant therapy (p  =  0.021). 
Nevertheless, this effect was lost when pN and pM were 
added into the analysis (p = 0.327, Table 3).
Tapasin predicts CD8+ CTL tumor infiltration
Next we tested the ability of tapasin expression to predict 
intratumoral CD8+ CTL invasion, as well as the odds of 
CTL tumor invasion in the presence and absence of tapa-
sin. Interestingly, a significantly higher presence of intra-
tumoral CD8+ CTLs was found in tapasin-high tumors 
(AUC 0.729, p < 0.001, OR 5.4; 95 % CI 2.6–11 and AUC 
0.650, p  =  0.002, OR 2.4 95  %  CI 1.4–4.2, respectively, 
Table 1). Tapasin also increases the likelihood of detect-
ing membranous MHC I expression in tumors by up 
to two-fold (p  =  0.035, OR 1.729, 95  % CI 1.04–2.88). 
Fig. 1 Immunohistochemistry staining. Analysis of HLA-ABC (MHC I), Tapasin, and CD8 staining in normal tissue and high and low intensity staining 
in tumor tissue
Page 4 of 6Sokol et al. J Transl Med  (2015) 13:279 
Interestingly, the effects of tapasin on CD8+ CTL tumor 
infiltration were independent of MHC I membrane 
expression (p = 0.008, OR 0.615, 95 % CI 0.429–0.882).
Association of tapasin expression and CD8+ CTL infiltration 
with survival in CRC
To assess whether the prognostic effect of tapasin can be 
seen as independent of CD8+ infiltration, we added it as 
a confounder in the Cox regression analysis. Under these 
conditions, tapasin lost its prognostic effect (p = 0.117). 
Additionally, we could see no benefit of a combined 
marker approach (tapasin and CD8+ CTL infiltration, 
data not shown).
Discussion
The aim of this study was to characterize the expres-
sion of tapasin as a potential prognostic tumor marker 
in CRC. We show that tapasin is decreased in invasive 
CRC, with this effect being even more pronounced in 
metastatic tumors. This is consistent with a previous 
study of tapasin expression in CRC and matched normal 
tissue, where gradual and increasing tapasin loss was like-
wise detected with tumor progression [16]. Expression of 
tapasin is also decreased in many other human cancers, 
including ovarian carcinoma, melanoma, glioblastoma, 
and salivary gland cancer [16–20]. We could further-
more correlate reduced tapasin expression with mark-
ers of increased invasiveness and systemic spread of the 
tumor, characterized by increased venous and lymphatic 
invasion, as well as distant metastasis. Importantly, we 
identify a strong survival advantage of patients bearing 
Table 1 Univariate analysis: association of  tapasin 
decrease with clinicopathological features
P-value OR 95 % CI AUC
Lymphatic invasion 0.005 2.04 1.25–3.33 0.62
Venous invasion 0.002 2.70 1.72–5.00 0.68
pT 0.882 1.04 0.61–1.79 0.50
pN 0.060 1.59 0.98–2.56 0.58
pM 0.004 2.86 1.41–5.88 0.73
Intratumoral CD8+ CTL <0.001 0.19 0.09–0.38 0.73
Tumor border configuration 0.017 2.22 1.15–4.35 0.62
Tumor grade 0.280 1.30 0.81–2.13 0.61
Gender 0.466 0.84 0.53–1.33 0.55
Adjuvant therapy 0.578 1.15 0.70–1.85 0.49
Table 2 Cox regression analysis of  survival—univariate 
analysis of single factors
HR 95 % CI P-value
Tapasin Baseline 1.00
By intensity 0.60 0.42–0.85 0.004
pT pT1-2 1.00
pT3-4 2.74 1.31–5.73 0.007
pN pN0 1.00
pN1-2 4.14 2.39–7.18 <0.001
pM pM0 1.00
pM1 6.08 3.38–10.92 <0.001
Adjuvant therapy None 1.00
Tx 1.48 0.89–2.48 0.143
Intratumoral CD8+ CTL Low 1.00
High 0.28 0.13–0.60 0.001
Fig. 2 Kaplan–Meier survival analysis of differential tapasin expres-
sion. Patients with high tapasin levels detected in the primary tumor 
have a higher 5-year survival rate (Black low tapasin: 0.321 ± 0.094, 
green high tapasin: 0.446 ± 0.142)
Table 3 Multivariable Cox regression analysis for  tapasin 
with TNM stage as confounding factors
Factors HR 95 % CI P-value
Tapasin
 Baseline 1
 By intensity 0.83 0.56–1.21 0.327
pT
 pT1-2 1
 pT3-4 1.38 0.62–3.05 0.431
pN
 pN0 1
 pN1-2 3.04 1.79–6.64 <0.001
pM
 pM0 1
 pM1 3.512 1.88–6.54 <0.001
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tapasin-positive tumors. Data from other groups have 
also shown similar consequences of tapasin decrease—in 
ovarian cancer it has been linked to higher stage, posi-
tive lymph nodes and considerably shorter survival time 
[17]. Likewise, in glioblastoma and salivary gland cancer, 
reduced tapasin expression correlated with shorter sur-
vival times [19, 20]. However, in our study, the prognos-
tic effect of tapasin was lost in a multivariate analysis, 
indicating that tapasin does not contribute independent 
information to a prognosis. Lastly we show that tapasin 
expression correlated with increased membranous stain-
ing of MHC I, and as a possible consequence, we detected 
a drastic increase of intratumoral CD8+ CTLs in tapasin-
positive tumors. Interestingly, the effect of tapasin on 
both CD8+ tumor infiltration and survival is independ-
ent of the amount of membranous MHC I. However, this 
result may be supported by multiple studies showing that 
tapasin expression not only promotes MHC I cell surface 
expression but that it increases total antigen presentation 
efficacy by ensuring the loading of a wide range of stable, 
highly affine peptides into the MHC I complex [21–24]. 
Consistent with these data, in a functional mouse study, 
Lou et al. demonstrated that tapasin expression restored 
susceptibility of tumor cells to CTL killing, and that 
animals with tapasin-expressing tumors had increased 
CD8+ CTL tumor infiltration and better survival [11]. 
As increased tumor infiltration by CD8+ CTLs has been 
demonstrated to strongly correlate with survival in CRC 
[2], we tested whether the prognostic effect of tapa-
sin might be a reflection of its correlation with tumor 
immune invasion. Indeed, when CD8+ CTL infiltration 
was added as a confounding factor in a multivariate Cox 
regression analysis, tapasin did not retain its prognos-
tic effect. These results suggests that the favorable sur-
vival effect of tapasin might be mediated both through 
an increase in antigen presentation quality and quantity. 
Tapasin expression thereby leads to the activation of the 
anti-tumoral immune response through increased recog-
nition and infiltration of the tumor by CD8+ CTLs.
The current study has several strengths. It conforms 
to the criteria for reporting recommendations for tumor 
marker studies (REMARK guidelines [25]). The analy-
ses have been performed using a very well characterized 
patient cohort for which full clinicopathological data is 
available, as well as information on treatment and over-
all survival. Protein expression was assessed using two 
tumor center and two tumor front punches in an ngTMA 
setup, ensuring equal staining conditions for all samples. 
The main weakness of this study is the lack of mechanis-
tic data. However, the literature on tapasin in the context 
of immune recognition includes multiple comprehen-
sive in vitro and in vivo functional studies which test the 
proposed molecular interactions. Therefore, this study 
focused on evaluating tapasin as a potential prognostic 
tumor marker in a translational setting.
Conclusions
To conclude, consistent with published functional stud-
ies linking tapasin to efficient antigen presentation and 
tumor immune recognition by CD8+ CTLs, reduced 
expression of tapasin is associated with tumor progres-
sion in CRC. However, our understanding of the role of 
tapasin in CRC might benefit from testing its expression 
at the very interface of tumor and immune cells within 
the tumor microenvironment. MHC I-mediated antigen 
presentation is frequently downregulated during single 
cell invasion [14, 26, 27]. Potentially the quality of anti-
gen presentation is also influenced by the conformation 
of HLA I molecules on the cell surface. Therefore, future 
studies could include evaluating the functional role and 
relevance of tapasin expression and MHC I conforma-
tion during single cell invasion and its correlation to the 
immune cell activation in the tumor microenvironment 
of CRC.
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